{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:52:12Z","timestamp":1791247932073,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:00:00Z","timestamp":1791072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metachromatic leukodystrophy (MLD) is a rapidly progressive leukodystrophy that leads to severe disability and early death if untreated. Autologous hematopoietic stem and progenitor cell gene therapy (HSPC-GT, atidarsagene autotemcel, arsa-cel) for early onset subtypes and allogenic hematopoietic stem cell transplantation (HSCT) for late onset disease substantially alters disease progression for early onset disease when administered before symptom onset, creating a strong rationale for newborn screening (NBS). At the same time, NBS technique for MLD in dried blood spots has recently been demonstrated to be robust and highly accurate. The aim was to give real-world results from the world\u2019s first NBS pilots for clinical management and treatment of identified children.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Between September 2021 and July 2025, 359,282 newborns underwent NBS for MLD in two different laboratories in Germany and Austria using a three-tier algorithm integrating sulfatide quantification, arylsulfatase A (ARSA) activity measurement, and\n                      <jats:italic>ARSA<\/jats:italic>\n                      sequencing. Screen-positive infants underwent a predefined care pathway including standardized confirmatory diagnostics, genotype-based and biochemical prediction of disease onset, clinical assessment and management guiding early treatment and surveillance at the qualified treatment center (QTC) in T\u00fcbingen.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Nine newborns screened positive and all were confirmed to have MLD (detection rate approximately 1 per 40,000). Based on genotype and leukocyte ARSA enzyme activity, disease onset prediction was possible in all of them. Seven infants were classified as having pre-symptomatic early-onset MLD and were referred for HSPC-GT. All treated infants showed preserved neurological function up to 30\u2009months after treatment (median 18.5\u2009months). Two infants predicted to develop late-onset MLD entered structured surveillance for treatment with HSCT and have remained clinically asymptomatic for CNS signs of disease. No false-positive or known false-negative results were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These results from our pilot programs demonstrate that NBS enables reliable early identification of MLD and support streamlined care pathways leading to timely intervention. Importantly, this study provides real-world evidence illustrating that NBS for MLD can enable timely, pre-symptomatic treatment and structured surveillance within standard national healthcare systems. These findings further substantiate the value of NBS for MLD at a critical moment as several countries consider national implementation of MLD screening.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-026-04620-y","type":"journal-article","created":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T02:43:10Z","timestamp":1791081790000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical management of metachromatic leukodystrophy cases identified in the German and Austrian Newborn screening pilots"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2506-1961","authenticated-orcid":false,"given":"Lucia","family":"Laugwitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Janzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Hegert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Nei\u00dfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Wacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Kern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadja","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Kehrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annina-Clarissa","family":"Jaeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Launer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Juengling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Zeyda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassiliki","family":"Konstantopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Graeter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Holzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Flaadt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Plecko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Neubauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Karall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Z\u00f6ggeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan T.","family":"Hold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Oliva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kasper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Beck-Woedl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Haack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"Rosewich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Groeschel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,4]]},"reference":[{"key":"4620_CR1","doi-asserted-by":"publisher","DOI":"10.1036\/ommbid.179","volume-title":"The online metabolic and molecular bases of inherited disease","author":"V Gieselmann","year":"2019","unstructured":"Gieselmann V, Kr\u00e4geloh-Mann I. Metachromatic leukodystrophy. In: Valle DL, Antonarakis S, Ballabio A, Beaudet AL, Mitchell GA, editors. The online metabolic and molecular bases of inherited disease. New York: McGraw-Hill Education; 2019. https:\/\/doi.org\/10.1036\/ommbid.179."},{"key":"4620_CR2","doi-asserted-by":"publisher","unstructured":"Asbreuk M, Schoenmakers DH, Adang LA, Beerepoot S, Bergner C, Bley A, et al. Metachromatic leukodystrophy: new therapy advancements and emerging research directions. Neurology. 2025;105(2):e213817. https:\/\/doi.org\/10.1212\/WNL.0000000000213817.","DOI":"10.1212\/WNL.0000000000213817"},{"issue":"1","key":"4620_CR3","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13023-024-03044-w","volume":"19","author":"SC Chang","year":"2024","unstructured":"Chang SC, Bergamasco A, Bonnin M, Bison\u00f3 TA, Moride Y. A systematic review on the birth prevalence of metachromatic leukodystrophy. Orphanet J Rare Dis. 2024;19(1):80. https:\/\/doi.org\/10.1186\/s13023-024-03044-w.","journal-title":"Orphanet J Rare Dis"},{"key":"4620_CR4","doi-asserted-by":"publisher","unstructured":"Kehrer C, Elg\u00fcn S, Raabe C, B\u00f6hringer J, Beck-W\u00f6dl S, Bevot A, et al. Association of age at onset and first symptoms with disease progression in patients with metachromatic leukodystrophy. Neurology. 2021;96(2):e255\u201366. https:\/\/doi.org\/10.1212\/WNL.0000000000011047.","DOI":"10.1212\/WNL.0000000000011047"},{"key":"4620_CR5","doi-asserted-by":"publisher","unstructured":"Beerepoot S, Schoenmakers DH, Fumagalli F, Groeschel S, Sch\u00f6ls L, Schiffmann R, et al. ARSA variants associated with cognitive decline and long-term preservation of motor function in metachromatic leukodystrophy. J Inher Metab Disea. 2025;48(5):e70072. https:\/\/doi.org\/10.1002\/jimd.70072.","DOI":"10.1002\/jimd.70072"},{"issue":"1","key":"4620_CR6","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13023-015-0313-y","volume":"10","author":"AA Boucher","year":"2015","unstructured":"Boucher AA, Miller W, Shanley R, Ziegler R, Lund T, Raymond G, et al. Long-term outcomes after allogeneic hematopoietic stem cell transplantation for metachromatic leukodystrophy: the largest single-institution cohort report. Orphanet J Rare Dis. 2015;10(1):94. https:\/\/doi.org\/10.1186\/s13023-015-0313-y.","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"4620_CR7","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1001\/jamaneurol.2016.2067","volume":"73","author":"S Groeschel","year":"2016","unstructured":"Groeschel S, K\u00fchl J-S, Bley AE, Kehrer C, Weschke B, D\u00f6ring M, et al. Long-term outcome of allogeneic hematopoietic stem cell transplantation in patients with juvenile metachromatic leukodystrophy compared with nontransplanted control patients. JAMA Neurol. 2016;73(9):1133\u201340. https:\/\/doi.org\/10.1001\/jamaneurol.2016.2067.","journal-title":"JAMA Neurol"},{"issue":"24","key":"4620_CR8","doi-asserted-by":"publisher","first-page":"3098","DOI":"10.1182\/blood-2016-03-708479","volume":"127","author":"DF van Rappard","year":"2016","unstructured":"van Rappard DF, Boelens JJ, van Egmond ME, Kuball J, van Hasselt PM, Oostrom KJ, et al. Efficacy of hematopoietic cell transplantation in metachromatic leukodystrophy: the Dutch experience. Blood. 2016;127(24):3098\u2013101. https:\/\/doi.org\/10.1182\/blood-2016-03-708479.","journal-title":"Blood"},{"issue":"16","key":"4620_CR9","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa2405727","volume":"392","author":"F Fumagalli","year":"2025","unstructured":"Fumagalli F, Calbi V, Gallo V, Zambon AA, Recupero S, Ciotti F, et al. Long-term effects of atidarsagene autotemcel for metachromatic leukodystrophy. N Engl J Med. 2025;392(16):1609\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2405727.","journal-title":"N Engl J Med"},{"issue":"10322","key":"4620_CR10","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/S0140-6736(21)02017-1","volume":"399","author":"F Fumagalli","year":"2022","unstructured":"Fumagalli F, Calbi V, Natali Sora MG, Sessa M, Baldoli C, Rancoita PMV, et al. Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1\/2 trial and expanded access. Lancet. 2022;399(10322):372\u201383. https:\/\/doi.org\/10.1016\/S0140-6736(21)02017-1.","journal-title":"Lancet"},{"issue":"5","key":"4620_CR11","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1002\/jmd2.12378","volume":"64","author":"C Horgan","year":"2023","unstructured":"Horgan C, Watts K, Ram D, Rust S, Hutton R, Jones S, et al. A retrospective cohort study of libmeldy (atidarsagene autotemcel) for MLD: what we have accomplished and what opportunities lie ahead. JIMD Rep. 2023;64(5):346\u201352. https:\/\/doi.org\/10.1002\/jmd2.12378.","journal-title":"JIMD Rep"},{"issue":"4","key":"4620_CR12","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3390\/ijns11040103","volume":"11","author":"L Laugwitz","year":"2025","unstructured":"Laugwitz L, Shenker A, Sluys EF, Pintat S, Whiteman D, Chanson C. Newborn screening for metachromatic leukodystrophy: a systematic literature review. Int J Neonatal Screen. 2025;11(4):103. https:\/\/doi.org\/10.3390\/ijns11040103.","journal-title":"Int J Neonatal Screen"},{"issue":"3","key":"4620_CR13","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41436-020-01017-5","volume":"23","author":"X Hong","year":"2021","unstructured":"Hong X, Daiker J, Sadilek M, Ruiz-Schultz N, Kumar AB, Norcross S, et al. Toward newborn screening of metachromatic leukodystrophy: results from analysis of over 27, 000 newborn dried blood spots. Genet Med. 2021;23(3):555\u201361. https:\/\/doi.org\/10.1038\/s41436-020-01017-5.","journal-title":"Genet Med"},{"issue":"1","key":"4620_CR14","doi-asserted-by":"publisher","first-page":"108349","DOI":"10.1016\/j.ymgme.2024.108349","volume":"142","author":"THY Wu","year":"2024","unstructured":"Wu THY, Brown HA, Church HJ, Kershaw CJ, Hutton R, Egerton C, et al. Improving newborn screening test performance for metachromatic leukodystrophy: recommendation from a pre-pilot study that identified a late-infantile case for treatment. Mol Genet Metab. 2024;142(1):108349. https:\/\/doi.org\/10.1016\/j.ymgme.2024.108349.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"4620_CR15","doi-asserted-by":"publisher","first-page":"108436","DOI":"10.1016\/j.ymgme.2024.108436","volume":"142","author":"S Bekri","year":"2024","unstructured":"Bekri S, Bley A, Brown HA, Chanson C, Church HJ, Gelb MH, et al. Higher precision, first tier newborn screening for metachromatic leukodystrophy using 16: 1-OH-sulfatide. Mol Genet Metab. 2024;142(1):108436. https:\/\/doi.org\/10.1016\/j.ymgme.2024.108436.","journal-title":"Mol Genet Metab"},{"issue":"13","key":"4620_CR16","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1056\/NEJMc2407165","volume":"391","author":"L Laugwitz","year":"2024","unstructured":"Laugwitz L, Mechtler TP, Janzen N, Oliva P, Kasper A-R, Teunissen CE, et al. Newborn screening and presymptomatic treatment of metachromatic leukodystrophy. N Engl J Med. 2024;391(13):1256\u201358. https:\/\/doi.org\/10.1056\/NEJMc2407165.","journal-title":"N Engl J Med"},{"issue":"2","key":"4620_CR17","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3390\/ijns11020030","volume":"11","author":"S Malvagia","year":"2025","unstructured":"Malvagia S, Bettiol A, Porcaro M, Mura M, Funghini S, Ombrone D, et al. Newborn screening for metachromatic leukodystrophy in Tuscany: the paradigm of a successful preventive medicine program. Int J Neonatal Screen. 2025;11(2):30. https:\/\/doi.org\/10.3390\/ijns11020030.","journal-title":"Int J Neonatal Screen"},{"key":"4620_CR18","unstructured":"European Observatory on Health Systems and Policies. Norway expands its newborn screening programme to 30 rare serious congenital disorders. Health systems and policy monitor. 2024. https:\/\/eurohealthobservatory.who.int\/monitors\/health-systems-monitor\/updates\/hspm\/norway-2020. 1 Aug 2026."},{"key":"4620_CR19","doi-asserted-by":"publisher","unstructured":"Langeveld M, Sirrs S, Schoenmakers DH, Fazio T, van der Klauw MM, Maillot F, et al. Screening for life: perspectives from adult metabolic specialists on newborn screening for inherited metabolic diseases. J Inher Metab Disea. 2025;48(4):e70057. https:\/\/doi.org\/10.1002\/jimd.70057.","DOI":"10.1002\/jimd.70057"},{"key":"4620_CR20","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ejpn.2024.03.003","volume":"49","author":"L Laugwitz","year":"2024","unstructured":"Laugwitz L, Schoenmakers DH, Adang LA, Beck-Woedl S, Bergner C, Bernard G, et al. Newborn screening in metachromatic leukodystrophy \u2013 European consensus-based recommendations on clinical management. Eur J Paediatr Neurol. 2024;49:141\u201354. https:\/\/doi.org\/10.1016\/j.ejpn.2024.03.003.","journal-title":"Eur J Paediatr Neurol"},{"issue":"3","key":"4620_CR21","doi-asserted-by":"publisher","first-page":"109138","DOI":"10.1016\/j.ymgme.2025.109138","volume":"145","author":"A Shaff","year":"2025","unstructured":"Shaff A, Basheeruddin K, Bekri S, Brown HA, Church HJ, Gianares J, et al. Newborn screening for metachromatic leukodystrophy: preparation of reagents and methodology for measurement of sulfatides and arylsulfatase a enzymatic activity in dried blood spots. Mol Genet Metab. 2025;145(3):109138. https:\/\/doi.org\/10.1016\/j.ymgme.2025.109138.","journal-title":"Mol Genet Metab"},{"key":"4620_CR22","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ejpn.2025.05.012","volume":"57","author":"DH Schoenmakers","year":"2025","unstructured":"Schoenmakers DH, Asbreuk MABC, Martin T, Datema M, Beerepoot S, Inbar-Feigenberg M, et al. Key lessons from the first international treatment eligibility committee: the case of metachromatic leukodystrophy. Eur J Paediatr Neurol. 2025;57:72\u201381. https:\/\/doi.org\/10.1016\/j.ejpn.2025.05.012.","journal-title":"Eur J Paediatr Neurol"},{"issue":"12","key":"4620_CR23","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.3390\/cells9122553","volume":"9","author":"S Strobel","year":"2020","unstructured":"Strobel S, Hesse N, Santhanakumaran V, Groeschel S, Bruchelt G, Kr\u00e4geloh-Mann I, et al. Optimization of enzyme essays to enhance reliability of activity measurements in leukocyte lysates for the diagnosis of metachromatic leukodystrophy and gangliosidoses. Cells. 2020;9(12):2553. https:\/\/doi.org\/10.3390\/cells9122553.","journal-title":"Cells"},{"issue":"3","key":"4620_CR24","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.ymgme.2022.09.009","volume":"137","author":"V Santhanakumaran","year":"2022","unstructured":"Santhanakumaran V, Groeschel S, Harzer K, Kehrer C, Elg\u00fcn S, Beck-W\u00f6dl S, et al. Predicting clinical phenotypes of metachromatic leukodystrophy based on the arylsulfatase a activity and the ARSA genotype? \u2013 chances and challenges. Mol Genet Metab. 2022;137(3):273\u201382. https:\/\/doi.org\/10.1016\/j.ymgme.2022.09.009.","journal-title":"Mol Genet Metab"},{"issue":"7","key":"4620_CR25","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1194\/jlr.D076588","volume":"58","author":"M Blomqvist","year":"2017","unstructured":"Blomqvist M, Bor\u00e9n J, Zetterberg H, Blennow K, M\u00e5nsson J-E, St\u00e5hlman M. High-throughput analysis of sulfatides in cerebrospinal fluid using automated extraction and UPLC-MS\/MS. J Lipid Res. 2017;58(7):1482\u201389. https:\/\/doi.org\/10.1194\/jlr.D076588.","journal-title":"J Lipid Res"},{"issue":"5","key":"4620_CR26","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and Genomics and the association for molecular pathology. Genet Med. 2015;17(5):405\u201324. https:\/\/doi.org\/10.1038\/gim.2015.30.","journal-title":"Genet Med"},{"key":"4620_CR27","unstructured":"European Medicines Agency. Libmeldy (atidarsagene autotemcel): summary of product characteristics. 2025. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/libmeldy. 1 Aug 2026. Amsterdam: European Medicines Agency."},{"key":"4620_CR28","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ejpn.2026.06.004","volume":"63","author":"L Laugwitz","year":"2026","unstructured":"Laugwitz L, Fumagalli F, Wehner K, Martin P, Kern J, Kaiser N, et al. European expert recommendations for comprehensive pre-treatment, treatment-phase and post-treatment care of patients with metachromatic leukodystrophy treated with autologous haematopoietic stem and progenitor cell gene therapy. Eur J Paediatr Neurol. 2026;63:46\u201359. https:\/\/doi.org\/10.1016\/j.ejpn.2026.06.004.","journal-title":"Eur J Paediatr Neurol"},{"issue":"1","key":"4620_CR29","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s13023-019-1113-6","volume":"14","author":"S Elg\u00fcn","year":"2019","unstructured":"Elg\u00fcn S, Waibel J, Kehrer C, van Rappard D, B\u00f6hringer J, Beck-W\u00f6dl S, et al. Phenotypic variation between siblings with metachromatic leukodystrophy. Orphanet J Rare Dis. 2019;14(1):136. https:\/\/doi.org\/10.1186\/s13023-019-1113-6.","journal-title":"Orphanet J Rare Dis"},{"issue":"10","key":"4620_CR30","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1093\/brain\/awaf157","volume":"148","author":"AA Zambon","year":"2025","unstructured":"Zambon AA, Rancoita PMV, Quattrini A, Butera C, Gentile F, Facchini M, et al. Effects of atidarsagene autotemcel gene therapy on peripheral nerves in late-infantile metachromatic leukodystrophy. Brain. 2025;148(10):3727\u201336. https:\/\/doi.org\/10.1093\/brain\/awaf157.","journal-title":"Brain"},{"issue":"1","key":"4620_CR31","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/brain\/awab304","volume":"145","author":"S Beerepoot","year":"2022","unstructured":"Beerepoot S, Heijst H, Roos B, Wamelink MMC, Boelens JJ, Lindemans CA, et al. Neurofilament light chain and glial fibrillary acidic protein levels in metachromatic leukodystrophy. Brain. 2022;145(1):105\u201318. https:\/\/doi.org\/10.1093\/brain\/awab304.","journal-title":"Brain"},{"issue":"1","key":"4620_CR32","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s13059-023-03001-z","volume":"24","author":"M Trinidad","year":"2023","unstructured":"Trinidad M, Hong X, Froelich S, Daiker J, Sacco J, Nguyen HP, et al. Predicting disease severity in metachromatic leukodystrophy using protein activity and a patient phenotype matrix. Genome Biol. 2023;24(1):172. https:\/\/doi.org\/10.1186\/s13059-023-03001-z.","journal-title":"Genome Biol"},{"key":"4620_CR33","unstructured":"Wilson JMG, Jungner G. Principles and practice of screening for disease. In: Public health papers No. 34. Geneva: World Health Organization; 1968. p. 1\u2013163."},{"key":"4620_CR34","doi-asserted-by":"publisher","unstructured":"Mohajer A, Sevagamoorthy A, Bean K, Mutua S, Pang F, Adang LA. Characterizing diagnostic delays in metachromatic leukodystrophy: a real-world data approach. J Inherit Metab Dis. 2025;48(4):e70049. https:\/\/doi.org\/10.1002\/jimd.70049.","DOI":"10.1002\/jimd.70049"},{"issue":"2","key":"4620_CR35","doi-asserted-by":"publisher","first-page":"108651","DOI":"10.1016\/j.ymgme.2024.108651","volume":"144","author":"K Bean","year":"2025","unstructured":"Bean K, Preston B, Adang LA, Pang F. Exploring the net monetary benefit of implementing newborn screening for metachromatic leukodystrophy in California. Mol Genet Metab. 2025;144(2):108651. https:\/\/doi.org\/10.1016\/j.ymgme.2024.108651.","journal-title":"Mol Genet Metab"},{"issue":"3","key":"4620_CR36","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3390\/ijns10030045","volume":"10","author":"K Bean","year":"2024","unstructured":"Bean K, Jones SA, Chakrapani A, Vijay S, Wu T, Church H, et al. Exploring the cost-effectiveness of newborn screening for metachromatic leukodystrophy (MLD) in the UK. Int J Neonatal Screen. 2024;10(3):45. https:\/\/doi.org\/10.3390\/ijns10030045.","journal-title":"Int J Neonatal Screen"},{"issue":"2","key":"4620_CR37","doi-asserted-by":"publisher","first-page":"107769","DOI":"10.1016\/j.ymgme.2023.107769","volume":"141","author":"K Bean","year":"2024","unstructured":"Bean K, Gelb MH, Adang LA, Chanson C, Pang F. Cost-effectiveness framework by tandem mass spectrometry (TMS) for newborn screening of metachromatic leukodystrophy (MLD) in the United States (US). Mol Genet Metab. 2024;141(2):107769. https:\/\/doi.org\/10.1016\/j.ymgme.2023.107769.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"4620_CR38","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s13023-025-03637-z","volume":"20","author":"C Kehrer","year":"2025","unstructured":"Kehrer C, Bevot A, Martin P, Raabe C, Gregor S, Kr\u00e4geloh-Mann I, et al. Healthcare utilization and disease burden in children with metachromatic leukodystrophy in Germany. Orphanet J Rare Dis. 2025;20(1):242. https:\/\/doi.org\/10.1186\/s13023-025-03637-z.","journal-title":"Orphanet J Rare Dis"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04620-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04620-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04620-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:02:52Z","timestamp":1791244972000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04620-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,4]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4620"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04620-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-9496450\/v1","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,4]]},"assertion":[{"value":"22 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"During the preparation of this manuscript, the authors used a large language model (LLM)-based AI assistant to support language editing and formatting. After using this tool, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.","order":1,"name":"Ethics","label":"Declaration of Generative AI and AI-assisted Technologies in the Writing Process","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"345"}}